Globus Medical (NYSE:GMED) Director David Davidar Sells 25,000 Shares

Globus Medical, Inc. (NYSE:GMED) Director David Davidar sold 25,000 shares of Globus Medical stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the transaction, the director directly owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Globus Medical Price Performance

Shares of GMED opened at $82.60 on Wednesday. The firm has a 50-day moving average of $86.08 and a 200-day moving average of $88.20. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40. The company has a market cap of $11.21 billion, a PE ratio of 19.21, a price-to-earnings-growth ratio of 1.61 and a beta of 0.95.

Globus Medical (NYSE:GMED) last posted its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. The company had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. Globus Medical’s quarterly revenue was up 27.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Analysts expect that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Institutional Trading of Globus Medical

Several hedge funds and other institutional investors have recently bought and sold shares of GMED. William Blair Investment Management LLC increased its holdings in Globus Medical by 17.2% in the 3rd quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock valued at $161,454,000 after buying an additional 414,134 shares during the period. ANTIPODES PARTNERS Ltd increased its holdings in Globus Medical by 49,020.3% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 891,043 shares of the medical device company’s stock valued at $51,034,000 after buying an additional 889,229 shares during the period. Foresight Group Ltd Liability Partnership increased its holdings in Globus Medical by 160.7% in the 3rd quarter. Foresight Group Ltd Liability Partnership now owns 421,541 shares of the medical device company’s stock valued at $24,142,000 after buying an additional 259,870 shares during the period. Annex Advisory Services LLC bought a new position in Globus Medical in the 4th quarter valued at about $20,572,000. Finally, Kingdon Capital Management L.L.C. increased its holdings in Globus Medical by 51.6% in the 3rd quarter. Kingdon Capital Management L.L.C. now owns 257,650 shares of the medical device company’s stock valued at $14,756,000 after buying an additional 87,650 shares during the period. Institutional investors and hedge funds own 95.16% of the company’s stock.

Wall Street Analyst Weigh In

GMED has been the subject of a number of research reports. Wells Fargo & Company cut their target price on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Royal Bank Of Canada raised their target price on shares of Globus Medical from $115.00 to $120.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Wall Street Zen cut shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Truist Financial set a $115.00 target price on shares of Globus Medical in a research note on Wednesday, February 25th. Finally, Barclays raised their target price on shares of Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Globus Medical has an average rating of “Moderate Buy” and a consensus target price of $106.36.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.